This article was released as Pharm Edaily Premium Content on February 11, 2026, at 8:00 AM. [Kim Saemi, Edaily Reporter] Sentiment across South Korea’s biotech sector diverged sharply on Feb. 10 as AprilBio came under heavy selling pressure following disclosures of insider share sales ahead of key clinical 백경게임 milestones. In contrast Cellbion continued to rally on sustained optimism surrounding radiopharmaceutical therapy (RPT) while NEUROPHET advanced as its U.S. market entry became increasingly 바다신릴게임 tangible. AprilBio Co., Ltd. share price movement on Feb. 10 (Source: KG Zeroin MP Doctor) AprilBio Slides as Insider S 게임릴사이트 elling Clouds Clinical Momentum AprilBio shares reversed sharply lower after the company disclosed that several executives had sold significant portions of their holdings just weeks ahead of 릴게임예시 major clinical data readouts. The stock fell 10.42% during regular trading and extended losses to 14.96% in after-hours trading. According to KG Zeroin’s MP Doctor(formerly MarketPoint), Ap 바다이야기예시 rilBio closed at won 53,300, down won 6,200 from the previous session. In after hours trading, shares slid further to won 50,600 reflecting heightened investor unease. Between 2:48 p.m. and 2:53 p.m., the company filed three consecutive disclosures on insider transactions. Advisor Seo Sang jun and Executive Vice President Ji Su seon sold all of their remaining shares on Feb. 3 totaling 33,000 and 2,500 shares respectively. Director Jin Hong guk also sold 45,500 shares across five transactions between Feb. 3 and Feb. 9, leaving a balance of 10,000 shares. The timing amplified market sensitivity. AprilBio is scheduled to release Phase 2 data for its atopic dermatitis candidate APB-R3 in early March. In parallel, partner Lundbeck recently confirmed plans to initiate a Phase 2 trial of APB-A1 for thyroid eye disease (TED) later this year and to disclose Phase 1b results in June, placing multiple clinical catalysts in close succession. Against this backdrop the insider sales were widely interpreted as a negative signal. “There’s no question that disclosures like this, coming just ahead of early March clinical results have a significant market impact.” said Ui Joo We an analyst at Korea Investment & Securities. AprilBio emphasized that the sales were driven by personal reasons and stressed that executives still retain unexercised holdings. “We sincerely apologize for causing concern and confusion.” a company official said. Cellbion Co., Ltd. share price movement over the past three months (Source: KG Zeroin MP Doctor) RPT Optimism Persists as Cellbion Extends Rally Cellbion surged 22.12% to close at won 33,400, as investor interest in prostate cancer radiopharmaceutical therapy continued to build. The stock has been on a steady upward trajectory since early November, rising from a three-month low of won 16,560 on Nov. 10 to an intraday high of won 34,500. Over the past three months, shares have gained 49.1%. In December, Cellbion applied for conditional approval with Korea’s Ministry of Food and Drug Safety for pocuvotide a prostate cancer RPT. Expectations for early commercialization, alongside potential partnering opportunities based on Phase 2 results, have gradually been priced in, according to market observers. The company said there was no single short-term catalyst behind the move. “The conditional approval review is progressing smoothly and we are steadily executing our development and regulatory plan.” a Cellbion official said. “Broader market interest in the RPT space appears to be driving a re-rating.” NEUROPHET Inc. share price movement on Feb. 10 (Source: KG Zeroin MP Doctor) NEUROPHET Rallies as U.S. Market Entry Takes Shape AI-based neuroimaging specialist NEUROPHET rose 13.7% to won 30,700 as expectations grew around its U.S. expansion and commercialization prospects. The company announced a supply agreement with University of Washington for its flagship solutions, Neurophet AQUA and Neurophet SCALE PET. The deal marks the company’s first tangible U.S. commercial milestone following the establishment of a U.S. subsidiary in October and the appointment of Josh Cohen as Head of Americas in December. Neurophet AQUA provides ultra fast quantitative analysis of brain MRI scans to assess atrophy and white matter degeneration supporting personalized reports for neurodegenerative diseases such as Alzheimer’s and vascular dementia. Neurophet SCALE PET offers automated standardized uptake value ratio (SUVR) quantification across multiple PET tracers, including amyloid-β, tau, FDG and dopamine. “Securing a supply agreement with the University of Washington has strengthened expectations for a full scale U.S. rollout which likely supported today’s share price move.” a NEUROPHET official said. 김새미 (bird@edaily.co.kr)